In an article by Xencor President and CEO Bassil Dahiyat, published in Pharmaceutical Executive on 4 November 2009, tables are presented on new technologies for creating ‘biobetter’ follow-on biologics (FOBs) and potential ‘Big Pharma’ players in FOBs.
Innovation over imitation: New FOBs technologies, players
Biosimilars/General
|
Posted 03/02/2010
0
Post your comment
| New technologies to create the next generation of biologicals: the ‘biobetters’ | |
| Technology | Advantages |
| Antibody and protein engineering, e.g., antibody Fc engineering | - Improved potency - Superior half-life and dosing - New IP exclusivity period |
| Cell line technologies | - Improved safety - Scalability - Increased productivity |
| Manufacturing technologies | - Enhanced stability and delivery - Improved formulation |
| Potential pharmaceutical players in FOBs | |
| Company | Biologicals capabilities |
| Amgen | - Established biologicals manufacturer
- Track record of launching next-generation |
| AstraZeneca | - Medimmune facility acquisition; biologicals expertise |
| Biogen Idec | - Established biologicals manufacturer |
| Boehringer Ingelheim | - Kemwell facility collaboration - Strategic alliance with Laureate Pharma - Partnership with Inno Biologics |
| Daiichi-Sankyo | - Ranbaxy asset acquisition - License agreement with Crucell and DSM Biologics |
| Eli Lilly | - ImClone asset acquisition |
| Merck | - GlycoFi technology - Insmed facility acquisition - BioVentures Unit, plan to launch 6 FOBs 2012- 2017 |
| Boehringer Ingelheim | - Kemwell facility collaboration - Strategic alliance with Laureate Pharma - Partnership with Inno Biologics |
| Novartis | - Sandoz generics division - Dedicated biologicals unit |
| Pfizer | - Aurobindo collaboration: generics expertise - Pharmacia/Chesterfield facility acquisition - PowderMed and Rinat Neurosciences acquisitions |
(see also, Innovation over imitation - How to deliver FOBs on the bottom line, Innovation over imitation: Charting the FOBs landscape, Innovation over imitation: Tools to compete and win with ‘biobetter’ FOBs, Innovation over imitation: High-cost biosimilar FOB development, slow uptake and Innovation over imitation: ‘Biobetter’ follow-on biologics)
Reference:
Bassil Dahiyat. Innovation Over Imitation. Pharmaceutical Executive. 2009 November 4.
Source: Pharmaceutical Executive
Research
Reaching ESG goals in pharmaceutical development
What is the future for the US biosimilar interchangeability designation
News
FDA approves ustekinumab biosimilar Starjemza
EMA recommend approval for aflibercept, ustekinumab, and pegfilgrastim biosimilars
Related content
Chinese biosimilars go global: growth, partnerships, and challenges
Biosimilars/General Posted 30/04/2025
IFPMA publishes position on pharmacy-mediated substitution for biosimilars
Biosimilars/General Posted 21/03/2025
The ustekinumab shift: biosimilars displace Stelara’s market leadership
Biosimilars/General Posted 12/03/2025
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment